A Rare Disease with an Intensive Surveillance Requirement
Malignant peritoneal mesothelioma affects the peritoneal lining of the abdomen. It is rare. For many patients, cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is the strongest treatment option available. A multi-institutional study published in the Journal of Clinical Oncology reported a median overall survival of 53 months and a five-year survival rate of approximately 47 percent in patients who received CRS and HIPEC - results that far exceed what systemic therapy alone achieves in this disease.
This result matters. Patients who stay well for five or more years after CRS and HIPEC must be carefully watched throughout that time. Clinics that don't follow a solid tracking schedule risk missing cancer coming back, delaying a second surgery, and losing the benefits of the first operation.
What the Standard Post-HIPEC Protocol Looks Like
Most peritoneal oncology programs build post-HIPEC surveillance around two repeating intervals. A retrospective single-center analysis of CRS and HIPEC outcomes described a representative protocol: clinical examination every three months and a thorax-abdomen CT scan every six months. Some programs add blood tests for mesothelin-related peptide (SMRP), including serum biomarkers at each clinic visit. Others use FDG-PET/CT for patients with unclear CT findings.
By oncology standards, this is a lot of appointments. Over five years, a patient with a three-month check-up and six-month CT schedule has about 20 clinic visits and 10 CT scans. Each one needs scheduling, results sent to the doctor, and notes in the chart. That is not mainly a paperwork problem. It is a workflow problem. When clinics treat each appointment as separate instead of as part of a plan, the schedule breaks down. Appointments get missed. Cancers that earlier imaging would have caught are found later and at a more advanced stage.
Why Schedules Slip in Practice
Peritoneal mesothelioma is rare enough that most oncology clinics treat only a handful of post-HIPEC patients at any given time. This rarity creates a specific problem. In common diseases, schedulers learn patterns through repetition. Coordinators understand the rhythms. The software is set up for common cases. For rare diseases, doctors must write the protocol into the system and enforce it at every step. Without software that shows these intervals automatically, the enforcement stays manual.
Manual follow-up depends on someone remembering. In a busy oncology practice, that means a coordinator checking a spreadsheet, a physician noticing an overdue flag in a chart, or a patient calling in because they remember an appointment was due. All three of those methods fail regularly. Research on care continuity in oncology settings has found that scheduling gaps happen because of unclear appointment systems and busy coordinators, not because doctors make mistakes.
A second reason schedules slip is how long the surveillance period is. For a patient who remains cancer-free, a three-month follow-up schedule maintained over five years can begin to feel routine. That sense of routine reduces urgency. A coordinator may put off rescheduling a canceled appointment. A physician may delay an imaging scan because the previous images were clear. These are not unreasonable choices taken alone. When added together across a small group of complex patients, they create systematic gaps.
A third factor is when care gets split. CRS and HIPEC for peritoneal mesothelioma is often done at a high-volume cancer center, while ongoing surveillance happens at a community clinic closer to the patient's home. When the surgical center and the follow-up clinic use different computer systems and separate schedules, surveillance records aren't connected. The community clinic may not see what the surgical center ordered, and the reverse is equally common.
The Cost of a Missed Surveillance Interval
Recurrence in peritoneal mesothelioma is not a remote risk. Medical experts have argued that patients with malignant peritoneal mesothelioma deserve long-term surveillance because cancer can come back in different ways and early detection matters. This argument is important because repeat CRS and HIPEC is an option for some patients with isolated recurrence. Early detection is necessary for eligibility.
A patient whose six-month CT is delayed by three or four months because the clinic had no automated reminder misses that window. If imaging shows cancer has come back at a later stage, a second surgery may no longer be possible. The missed interval is not just an administrative problem. It is a clinical one. For clinic leaders, it is also a documentation problem: they established a protocol in the chart but did not follow it on time.
What Systematic Follow-Up Tracking Requires
Closing this gap requires three connected operational capabilities.
The first is a disease-specific patient timeline. A peritoneal mesothelioma patient after HIPEC has a different surveillance schedule than a thyroid cancer patient on active monitoring or a colon cancer patient two years out from surgery. A generic calendar that books appointments on request will not enforce disease-specific intervals. The platform needs the timeline programmed in, and it needs to alert staff when appointments are coming up or overdue.
The second is real-time visibility when doctors see patients. A clinician seeing a patient for any reason should be able to check in under 30 seconds whether the six-month CT is upcoming and booked. That means the appointment system and medical records need to be connected so staff do not have to manually check both places.
The third is when different doctors' offices work together. When patients go to both a cancer center and a community clinic, both teams need to see the same schedule. When the offices share secure schedules, a missed appointment at one office will not be invisible to the other office for weeks. For more about how this works, see our article on why treatment timelines matter for oncology clinics. You can see similar patterns in our analysis of lab monitoring in appendiceal cancer clinics. If you need to track biomarkers and imaging, the methods from our piece on mesothelin tracking in pleural mesothelioma also work for SMRP tracking in peritoneal cancer.
Platform Architecture for Rare-Disease Follow-Up
Post-HIPEC surveillance for peritoneal mesothelioma faces the same challenge as all rare peritoneal surface cancers. Low patient volume means low automatic pattern reinforcement. Long follow-up windows mean long exposure to scheduling drift. Care getting split means incomplete records. A system built for common cancers does not work well when scheduling really matters - in rare cancer care. Peritoneal mesothelioma is not a common cancer. It deserves a scheduling system built for it.
Demos take 30 minutes and show how post-HIPEC surveillance works with your clinic's workflow. Book a demo to see how the system handles rare-disease follow-up.